TC Biopharm (NASDAQ:TCBP) versus Fate Therapeutics (NASDAQ:FATE) Critical Review

TC Biopharm (NASDAQ:TCBP) and Fate Therapeutics (NASDAQ:FATE) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, dividends, profitability, institutional ownership, risk and valuation.

Volatility & Risk

TC Biopharm has a beta of 0.01, meaning that its stock price is 99% less volatile than the S&P 500. Comparatively, Fate Therapeutics has a beta of 2.23, meaning that its stock price is 123% more volatile than the S&P 500.

Earnings & Valuation

This table compares TC Biopharm and Fate Therapeutics”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TC Biopharm	$4.76 million	0.06	-$7.35 million	N/A	N/A
Fate Therapeutics	$13.34 million	10.96	-$160.93 million	($1.49)	-0.86

TC Biopharm has higher earnings, but lower revenue than Fate Therapeutics.

Profitability

This table compares TC Biopharm and Fate Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
TC Biopharm	N/A	N/A	N/A
Fate Therapeutics	-1,325.43%	-45.88%	-33.95%

Institutional & Insider Ownership

16.3% of TC Biopharm shares are held by institutional investors. Comparatively, 97.5% of Fate Therapeutics shares are held by institutional investors. 15.4% of TC Biopharm shares are held by company insiders. Comparatively, 5.5% of Fate Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for TC Biopharm and Fate Therapeutics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TC Biopharm	0	0	1	0	3.00
Fate Therapeutics	0	7	2	0	2.22

TC Biopharm presently has a consensus target price of $48.00, indicating a potential upside of 6,948.46%. Fate Therapeutics has a consensus target price of $4.14, indicating a potential upside of 224.93%. Given TC Biopharm’s stronger consensus rating and higher possible upside, equities research analysts clearly believe TC Biopharm is more favorable than Fate Therapeutics.

Summary

TC Biopharm beats Fate Therapeutics on 7 of the 12 factors compared between the two stocks.

About TC Biopharm

TC Biopharm (Holdings) Plc, a clinical-stage biopharmaceutical company, focuses on the development of immunotherapy products based on its allogeneic gamma delta T cell platform. Its product pipeline includes OmnImmune, an allogeneic unmodified gamma-delta T cell therapy product under Phase 2/3 trails for the treatment of acute myeloid leukemia; and ImmuniStim, an unmodified cell therapy to treat viral infections as well as cancers. The company was founded in 2013 and is headquartered in Motherwell, the United Kingdom.

About Fate Therapeutics

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.